313 related articles for article (PubMed ID: 16751014)
1. Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
Pérez de Diego R; López-Granados E; Pozo M; Rodríguez C; Sabina P; Ferreira A; Fontan G; García-Rodríguez MC; Alemany S
J Allergy Clin Immunol; 2006 Jun; 117(6):1462-9. PubMed ID: 16751014
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA.
Gaspar HB; Lester T; Levinsky RJ; Kinnon C
Clin Exp Immunol; 1998 Feb; 111(2):334-8. PubMed ID: 9486400
[TBL] [Abstract][Full Text] [Related]
3. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis.
Kanegane H; Futatani T; Wang Y; Nomura K; Shinozaki K; Matsukura H; Kubota T; Tsukada S; Miyawaki T
J Allergy Clin Immunol; 2001 Dec; 108(6):1012-20. PubMed ID: 11742281
[TBL] [Abstract][Full Text] [Related]
4. Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells.
Zorn CN; Keck S; Hendriks RW; Leitges M; Freudenberg MA; Huber M
Cell Signal; 2009 Jan; 21(1):79-86. PubMed ID: 18848985
[TBL] [Abstract][Full Text] [Related]
5. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages.
de Weers M; Verschuren MC; Kraakman ME; Mensink RG; Schuurman RK; van Dongen JJ; Hendriks RW
Eur J Immunol; 1993 Dec; 23(12):3109-14. PubMed ID: 8258324
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
Lindvall JM; Blomberg KE; Väliaho J; Vargas L; Heinonen JE; Berglöf A; Mohamed AJ; Nore BF; Vihinen M; Smith CI
Immunol Rev; 2005 Feb; 203():200-15. PubMed ID: 15661031
[TBL] [Abstract][Full Text] [Related]
7. Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children.
Noordzij JG; de Bruin-Versteeg S; Comans-Bitter WM; Hartwig NG; Hendriks RW; de Groot R; van Dongen JJ
Pediatr Res; 2002 Feb; 51(2):159-68. PubMed ID: 11809909
[TBL] [Abstract][Full Text] [Related]
8. Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia.
Nonoyama S; Tsukada S; Yamadori T; Miyawaki T; Jin YZ; Watanabe C; Morio T; Yata J; Ochs HD
J Immunol; 1998 Oct; 161(8):3925-9. PubMed ID: 9780159
[TBL] [Abstract][Full Text] [Related]
9. A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia.
López-Granados E; Pérez de Diego R; Ferreira Cerdán A; Fontán Casariego G; García Rodríguez MC
J Allergy Clin Immunol; 2005 Sep; 116(3):690-7. PubMed ID: 16159644
[TBL] [Abstract][Full Text] [Related]
10. Expression of Bruton's agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells.
Smith CI; Baskin B; Humire-Greiff P; Zhou JN; Olsson PG; Maniar HS; Kjellén P; Lambris JD; Christensson B; Hammarström L
J Immunol; 1994 Jan; 152(2):557-65. PubMed ID: 8283037
[TBL] [Abstract][Full Text] [Related]
11. X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.
Maekawa K; Yamada M; Okura Y; Sato Y; Yamada Y; Kawamura N; Ariga T
Blood Cells Mol Dis; 2010 Apr; 44(4):300-4. PubMed ID: 20122858
[TBL] [Abstract][Full Text] [Related]
12. Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region.
Maas A; Dingjan GM; Grosveld F; Hendriks RW
J Immunol; 1999 Jun; 162(11):6526-33. PubMed ID: 10352268
[TBL] [Abstract][Full Text] [Related]
13. X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease.
Mattsson PT; Vihinen M; Smith CI
Bioessays; 1996 Oct; 18(10):825-34. PubMed ID: 8885720
[TBL] [Abstract][Full Text] [Related]
14. Identification of nine novel mutations in the Bruton's tyrosine kinase gene in X-linked agammaglobulinaemia patients.
Orlandi P; Ritis K; Moschese V; Angelini F; Arvanitidis K; Speletas M; Sideras P; Plebani A; Rossi P
Hum Mutat; 2000 Jan; 15(1):117. PubMed ID: 10612838
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype correlation in Bruton's tyrosine kinase deficiency.
Teimourian S; Nasseri S; Pouladi N; Yeganeh M; Aghamohammadi A
J Pediatr Hematol Oncol; 2008 Sep; 30(9):679-83. PubMed ID: 18776760
[TBL] [Abstract][Full Text] [Related]
16. xid affects events leading to B cell cycle entry.
Brorson K; Brunswick M; Ezhevsky S; Wei DG; Berg R; Scott D; Stein KE
J Immunol; 1997 Jul; 159(1):135-43. PubMed ID: 9200448
[TBL] [Abstract][Full Text] [Related]
17. Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.
Brunner C; Kreth HW; Ochs HD; Schuster V
J Clin Immunol; 2002 Jul; 22(4):244-51. PubMed ID: 12148599
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic analysis of X-linked hypogammaglobulinemia and isolated growth hormone deficiency.
Stewart DM; Notarangelo LD; Kurman CC; Staudt LM; Nelson DL
J Immunol; 1995 Sep; 155(5):2770-4. PubMed ID: 7650402
[TBL] [Abstract][Full Text] [Related]
19. Genomic organization of mouse and human Bruton's agammaglobulinemia tyrosine kinase (Btk) loci.
Sideras P; Müller S; Shiels H; Jin H; Khan WN; Nilsson L; Parkinson E; Thomas JD; Brandén L; Larsson I
J Immunol; 1994 Dec; 153(12):5607-17. PubMed ID: 7989760
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia.
Lopez-Herrera G; Berron-Ruiz L; Mogica-Martinez D; Espinosa-Rosales F; Santos-Argumedo L
Mol Immunol; 2008 Feb; 45(4):1094-8. PubMed ID: 17765309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
